1AE:ETR
argenx SE
€824,80
arrow_downward
-1,03%(-8,60) 1D
7 ຕ.ລ., 11 ໂມງ 6 ນາທີ 41 ວິນາທີ GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 1AE...
Open
€827,40
High
€827,40
Low
€824,80
Mkt. cap
51,82 ຕື້
Avg. vol.
73,00
Volume
65,00
P/E ratio
35,16
52-wk high
€922,00
52-wk low
€574,20
EPS
€23,46
No. of employees
2 ພັນ
Open
€827,40
High
€827,40
Low
€824,80
Mkt. cap
51,82 ຕື້
Avg. vol.
73,00
Volume
65,00
P/E ratio
35,16
52-wk high
€922,00
52-wk low
€574,20
EPS
€23,46
No. of employees
2 ພັນ
News stories
From web sources and news partners
AD HOC NEWS
·
3 ຊົ່ວໂມງກ່ອນ
Goldman Sachs raises target for Argenx stock to EUR 982.00
Investing.com UK
·
14 ຊົ່ວໂມງກ່ອນ
Halozyme expands argenx collaboration with two new targets By Investing.com
Stock Titan
·
14 ຊົ່ວໂມງກ່ອນ
A drug-delivery partnership expands from six exclusive targets to eight.
AD HOC NEWS
·
18 ຊົ່ວໂມງກ່ອນ
argenx stock: New VYVGART data span myasthenia gravis and CIDP
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About argenx SE